Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin in Acute Ischemic Stroke
NCT05857046Phase 3Recruiting
- Sponsor
- Coordinación de Investigación en Salud
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Melatonin Group with Placebo Group (2 arms). Primary endpoint: Change in functional outcome and mortality at 3 months. Started Mar 2024; status: recruiting.
02
Drugs
melatonin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05857046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857046.